TRAX logo

TRAX First Tracks Biotherapeutics Inc

NASDAQ Global Select · Biotechnology · Healthcare

$44.50
+0.93 (+2.13%)

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

Market Cap: $1.87Bwww.firsttracksbio.com

Price

No data yet.

Social Signal Score

66
5d
—
30d
70
2 mentions
—
60d
63
5 mentions
—
90d
65
6 mentions
—
news: 6

Analyst Ratings

10 analysts
Buyconsensus
Strong Buy 0Buy 10Hold 0Sell 0Strong Sell 0
Avg price target$72.44+62.8%
Low $57Median $65High $110
Current Consensus

Revenue

$0.00
$0.00
Mar 2025Sep 2026

Analyst Estimates

FY2025
$-4.85
$-4.85–$-4.85
3 analysts
FY2026
$-3.99
$-4.28–$-3.85
6 analysts
FY2027
$-3.46
$-4.30–$-2.48
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Daniel R. Faga
Sector
Healthcare
Industry
Biotechnology
Employees
104
Beta
3.37
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
54.84
www.firsttracksbio.com